Noom has launched Noom Band, a wearable device designed to integrate continuous health monitoring into its metabolic health platform. Developed in partnership with Sensor Bio, the wrist-worn device tracks heart rate, heart rate variability, blood oxygen saturation, sleep and physical activity. Noom plans to make the wearable available to its employer and health plan customers beginning in early 2027, without additional upfront costs.
The device will connect directly to the Noom app, allowing physiological data to inform personalized behavioral interventions and weight management programs. By incorporating continuous monitoring, Noom aims to provide a more comprehensive understanding of members' health beyond traditional weight tracking, helping users identify patterns in sleep, activity and cardiovascular health.
The launch builds on Noom's expansion beyond its original weight loss app into a broader metabolic health platform. Its existing services include Noom Med, which offers virtual medical care and prescription weight loss treatments, alongside at-home biomarker testing. Adding a proprietary wearable allows Noom to combine medication management, behavioral coaching, diagnostic information and ongoing health monitoring within a single ecosystem.
According to company data, an analysis of 144,000 Noom Med members taking GLP-1 medications found that those using connected wearables were 34% more likely to lose 20 pounds by the fourth month of treatment. A separate analysis found that Noom Band users taking GLP-1 medications increased their sleep duration by an average of 90 minutes per week after two months, with larger improvements among members who initially experienced insufficient sleep. These observational findings do not establish that wearable use directly caused the improvements.
Noom also plans to use the wearable to encourage engagement by allowing members to unlock the device after reaching early program milestones. The company believes that continuous health monitoring can help users remain engaged with their treatment plans and support progress toward weight loss and metabolic health goals.
The company is preparing to participate in the Centers for Medicare & Medicaid Services' ACCESS Model, focusing on cardio-kidney-metabolic conditions such as obesity, prediabetes and diabetes. Under the model, Noom plans to combine its behavioral health program with wearable monitoring and connected blood pressure devices to support measurable improvements in weight, blood pressure and HbA1c.
Click here to read the original news story.